Vascular Fibrosis in Aging and Hypertension: Molecular Mechanisms and Clinical Implications

Canadian Journal of Cardiology

Volumn 32, Issue 5, 2016, Pages 659-668

  Harvey, Adam ^a   Montezano, Augusto C ^a   Lopes, Rheure Alves ^a   Rios, Francisco ^a   Touyz, Rhian M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN 1; GALECTIN 3; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; VASOACTIVE AGENT;

AGING; ARTERIAL STIFFNESS; ARTERY COMPLIANCE; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR MATRIX; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR DISEASE; VASCULAR FIBROSIS; VASCULAR REMODELING; FIBROSIS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; VASCULAR ENDOTHELIUM;

AGING; ANGIOTENSIN II; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FIBROSIS; HUMANS; HYPERTENSION; MATRIX METALLOPROTEINASES; RISK FACTORS; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR STIFFNESS;

EID: 84964403676     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2016.02.070     Document Type: Review

References (96)

1. World Health Organization, International Society of Hypertension Writing Group 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003, 21:1983-1992.
2. Baker P.B., Baba N., Boesel C.P. Cardiovascular abnormalities in progeria. Case report and review of the literature. Arch Pathol Lab Med 1981, 105:384-386.
3. Huveneers S., Daemen M.J., Hordijk P.L. Between Rho(k) and a hard place: the relation between vessel wall stiffness, endothelial contractility, and cardiovascular disease. Circ Res 2015, 116:895-908.
4. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. Circulation 2003, 107:139-146.
5. Stout L.C., Whorton E.B., Vaghela M. Pathogenesis of diffuse intimal thickening (DIT) in non-human primate thoracic aortas. Atherosclerosis 1983, 47:1-6.
6. Lopes R.A., Neves K.B., Tostes R.C., Montezano A.C., Touyz R.M. Downregulation of nuclear factor erythroid 2-related factor and associated antioxidant genes contributes to redox-sensitive vascular dysfunction in hypertension. Hypertension 2015, 66:1240-1250.
7. AlGhatrif M., Strait J.B., Morrell C.H., et al. Longitudinal trajectories of arterial stiffness and the role of blood pressure: the Baltimore Longitudinal Study of Aging. Hypertension 2013, 62:934-941.
8. AlGhatrif M., Lakatta E.G. The conundrum of arterial stiffness, elevated blood pressure, and aging. Curr Hypertens Rep 2015, 17:1-9.
9. Nilsson P.M., Boutouyrie P., Cunha P., et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens 2013, 31:1517-1526.
10. Laurent S., Boutouyrie P. The structural factor of hypertension: large and small artery alterations. Circ Res 2015, 116:1007-1021.
11. Laurent S., Cockcroft J., Van Bortel L., et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588-2605. European Network for Noninvasive Investigation of Large Arteries.
12. Van Bortel L.M., Laurent S., Boutouyrie P., et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 2012, 30:445-448. Artery Society, European Society of Hypertension Working Group on Vascular Structure and FunctionEuropean Society of Hypertension Working Group on Vascular Structure and Function, European Network for Noninvasive Investigation of Large ArteriesEuropean Network for Noninvasive Investigation of Large Arteries.
13. Kotsis V., Stabouli S., Karafillis I., Nilsson P. Early vascular aging and the role of central blood pressure. J Hypertens 2011, 29:1847-1853.
14. Kida Y., Goligorsky M.S. Sirtuins, cell senescence, and vascular aging. Can J Cardiol 2016, 32:634-641.
15. Lakatta E.G. The reality of aging viewed from the arterial wall. Artery Res 2013, 7:73-80.
16. Wang Z., Griffin M. TG2, a novel extracellular protein with multiple functions. Amino Acids 2012, 42:939-949.
17. Petersen-Jones H.G., Johnson K.B., Hitomi K., et al. Transglutaminase activity is decreased in large arteries from hypertensive rats compared with normotensive controls. Am J Physiol Heart Circ Physiol 2015, 308:H592-H602.
18. Chakraborti S., Mandal M., Das S., Mandal A., Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003, 253:269-285.
19. Giannandrea M., Parks W.C. Diverse functions of matrix metalloproteinases during fibrosis. Dis Model Mech 2014, 7:193-203.
20. Iimuro Y., Nishio T., Morimoto T., et al. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 2003, 124:445-458.
21. Prakobwong S., Yongvanit P., Hiraku Y., et al. Involvement of MMP-9 in peribiliary fibrosis and cholangiocarcinogenesis via Rac1-dependent DNA damage in a hamster model. Int J Cancer 2010, 127:2576-2587.
22. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005, 85:1-31.
23. Wang M., Kim S.H., Monticone R.E., Lakatta E.G. Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis. Hypertension 2015, 65:698-703.
24. Wang M., Zhao D., Spinetti G., et al. Matrix metalloproteinase 2 activation of transforming growth factor-beta1 (TGF-beta1) and TGF-beta1-type II receptor signalling within the aged arterial wall. Arterioscler Thromb Vasc Biol 2006, 26:1503-1509.
25. Wang M., Zhang J., Telljohann R., et al. Chronic matrix metalloproteinase inhibition retards age-associated arterial proinflammation and increase in blood pressure. Hypertension 2012, 60:459-466.
26. Zavaczki E., Jeney V., Agarwal A., et al. Hydrogen sulfide inhibits the calcification and osteoblastic differentiation of vascular smooth muscle cells. Kidney Int 2011, 80:731-739.
27. Li Z., Froehlich J., Galis Z.S., Lakatta E.G. Increased expression of matrix metalloproteinase-2 in the thickened intima of aged rats. Hypertension 1999, 33:116-123.
28. Horn M.A., Graham H.K., Richards M.A., et al. Age-related divergent remodeling of the cardiac extracellular matrix in heart failure: collagen accumulation in the young and loss in the aged. J Mol Cell Cardiol 2012, 53:82-90.
29. Bonnema D.D., Webb C.S., Pennington W.R., et al. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail 2007, 13:530-540.
30. Wang M., Takagi G., Asai K., et al. Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates. Hypertension 2003, 41:1308-1316.
31. Wang M., Zhang J., Jiang L.Q., et al. Proinflammatory profile within the grossly normal aged human aortic wall. Hypertension 2007, 50:219-227.
32. Ruiz-Ortega M., Rodriguez-Vita J., Sanchez-Lopez E., Carvajal G., Egido J. TGF-beta signalling in vascular fibrosis. Cardiovasc Res 2007, 74:196-206.
33. Douillet C.D., Velarde V., Christopher J.T., et al. Mechanisms by which bradykinin promotes fibrosis in vascular smooth muscle cells: role of TGF-beta and MAPK. Am J Physiol Heart Circ Physiol 2000, 279:H2829-H2837.
34. O'Callaghan C.J., Williams B. Mechanical strain-induced extracellular matrix production by human vascular smooth muscle cells: role of TGF-beta(1). Hypertension 2000, 36:319-324.
35. Duncan M.R., Frazier K.S., Abramson S., et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J 1999, 13:1774-1786.
36. Rodriguez-Vita J., Sanchez-Lopez E., Esteban V., et al. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 2005, 111:2509-2517.
37. Li J.H., Huang X.R., Zhu H.J., et al. Advanced glycation end products activate Smad signalling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 2004, 18:176-178.
38. Gibbons G.H., Pratt R.E., Dzau V.J. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992, 90:456-461.
39. Itoh H., Mukoyama M., Pratt R.E., Gibbons G.H., Dzau V.J. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993, 91:2268-2274.
40. Sucosky P., Balachandran K., Elhammali A., Jo H., Yoganathan A.P. Altered shear stress stimulates upregulation of endothelial VCAM-1 and ICAM-1 in a BMP-4- and TGF-beta1-dependent pathway. Arterioscler Thromb Vasc Biol 2009, 29:254-260.
41. Rhyu D.Y., Yang Y., Ha H., et al. Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol 2005, 16:667-675.
42. Russo I., Frangogiannis N.G. Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol 2016, 90:84-93.
43. Takeshita K., Yamamoto K., Ito M., et al. Increased expression of plasminogen activator inhibitor-1 with fibrin deposition in a murine model of aging, "Klotho" mouse. Semin Thromb Hemost 2002, 28:545-554.
44. Hashimoto Y., Kobayashi A., Yamazaki N., et al. Relationship between age and plasma t-PA, PA-inhibitor, and PA activity. Thromb Res 1987, 46:625-633.
45. Yamamoto K., Takeshita K., Saito H. Plasminogen activator inhibitor-1 in aging. Semin Thromb Hemost 2014, 40:652-659.
46. Vlachopoulos C., Xaplanteris P., Aboyans V., et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis 2015, 241:507-532.
47. Oemar B.S., Luscher T.F. Connective tissue growth factor. Friend or foe?. Arterioscler Thromb Vasc Biol 1997, 17:1483-1489.
48. Ruperez M., Lorenzo O., Blanco-Colio L.M., et al. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 2003, 108:1499-1505.
49. van Almen G.C., Verhesen W., van Leeuwen R.E., et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell 2011, 10:769-779.
50. Bigot A., Jacquemin V., Debacq-Chainiaux F., et al. Replicative aging down-regulates the myogenic regulatory factors in human myoblasts. Biol Cell 2008, 100:189-199.
51. Van Kimmenade R.R., Januzzi J.L., Ellinor P.T., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006, 48:1217-1224.
52. De Boer R., van Veldhuisen D., Gansevoort R., et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012, 272:55-64.
53. Koopmans S.M., Bot F.J., Schouten H.C., Janssen J., van Marion A. The involvement of Galectins in the modulation of the JAK/STAT pathway in myeloproliferative neoplasia. Am J Blood Res 2012, 2:119-127.
54. Song X., Qian X., Shen M., et al. Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression. Biochim Biophys Acta 2015, 1853:513-521.
55. Calvier L., Miana M., Reboul P., et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013, 33:67-75.
56. Vergaro G., Prud'homme M., Fazal L., et al. Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice. Hypertension 2016, 67:606-612.
57. Mendoza-Torres E., Oyarzun A., Mondaca-Ruff D., et al. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Ther Adv Cardiovasc Dis 2015, 9:217-237.
58. Martinez-Martinez E., Calvier L., Fernandez-Celis A., et al. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension 2015, 66:767-775.
59. Messaoudi S., He Y., Gutsol A., et al. Endothelial Gata5 transcription factor regulates blood pressure. Nat Commun 2015, 6:8835.
60. Yu L., Ruifrok W.P., Meissner M., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013, 6:107-117.
61. Neves K., Nguyen Dinh Cat A., Lopes R.A., et al. Chemerin regulates crosstalk between adipocytes and vascular cells through Nox. Hypertension 2015, 66:657-666.
62. Krug A.W., Allenhofer L., Monticone R., et al. Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways. Hypertension 2010, 55:1476-1483.
63. Spiers J.P., Kelso E.J., Siah W.F., et al. Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade. J Hypertens 2005, 23:1717-1724.
64. Park J.B., Schiffrin E.L. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens 2002, 15:164-169.
65. Weigert C., Brodbeck K., Klopfer K., Häring H., Schleicher E. Angiotensin II induces human TGF-β1 promoter activation: similarity to hyperglycaemia. Diabetologia 2002, 45:890-898.
66. Montezano A.C., Paravicini T.M., Chignalia A.Z., et al. Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (nox5) regulation by angiotensin ii and endothelin-1 is mediated via calcium/calmodulin-dependent pathways in human endothelial cells. Circ Res 2010, 106:1363-1373.
67. Qi G., Jia L., Li Y., et al. Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. Cardiovasc Toxicol 2011, 11:157-167.
68. Carver K.A., Smith T.L., Gallagher P.E., Tallant E. Angiotensin-(1-7) prevents angiotensin II-induced fibrosis in cremaster microvessels. Microcirculation 2015, 22:19-27.
69. Ishidoya S., Morrissey J., McCracken R., Reyes A., Klahr S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995, 47:1285-1294.
70. Ruiz-Ortega M., Gonzalez S., Seron D., et al. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int 1995, 48:1778-1791.
71. AbouEzzeddine O.F., Haines P., Stevens S., et al. Galectin-3 in heart failure with preserved ejection fraction: a RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). JACC Heart Fail 2015, 3:245-252.
72. Li Z., Li J., Bu X., et al. Age-induced augmentation of p38 MAPK phosphorylation in mouse lung. Exp Gerontol 2011, 46:694-702.
73. Wu Z., Yu Y., Liu C., et al. Role of p38 mitogen-activated protein kinase in vascular endothelial aging: interaction with arginase-II and S6K1 signalling pathway. Aging (Albany NY) 2015, 7:70-81.
74. Hsieh C., Papaconstantinou J. The effect of aging on p38 signalling pathway activity in the mouse liver and in response to ROS generated by 3-nitropropionic acid. Mech Ageing Dev 2002, 123:1423-1435.
75. Pons M., Cousins S.W., Alcazar O., Striker G.E., Marin-Castaño M.E. Angiotensin II-induced MMP-2 activity and MMP-14 and basigin protein expression are mediated via the angiotensin II receptor type 1-mitogen-activated protein kinase 1 pathway in retinal pigment epithelium: implications for age-related macular degeneration. Am J Pathol 2011, 178:2665-2681.
76. Nakai K., Kawato T., Morita T., et al. Angiotensin II induces the production of MMP-3 and MMP-13 through the MAPK signalling pathways via the AT 1 receptor in osteoblasts. Biochimie 2013, 95:922-933.
77. Yaghooti H., Firoozrai M., Fallah S., Khorramizadeh M. Angiotensin II induces NF-κB, JNK and p38 MAPK activation in monocytic cells and increases matrix metalloproteinase-9 expression in a PKC-and Rho kinase-dependent manner. Braz J Med Biol Res 2011, 44:193-199.
78. Oelusarz A., Nichols L.A., Grunz-Borgmann E.A., et al. Overexpression of MMP-7 increases collagen 1A2 in the aging kidney. Physiol Rep 2013, 1:e00090.
79. Sangaralingham S.J., Wang B.H., Huang L., et al. Cardiorenal fibrosis and dysfunction in aging: imbalance in mediators and regulators of collagen. Peptides 2016, 76:108-114.
80. Odenbach J., Wang X., Cooper S., et al. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 2011, 57:123-130.
81. Sakurabayashi-Kitade S., Aoka Y., Nagashima H., et al. Aldosterone blockade by spironolactone improves the hypertensive vascular hypertrophy and remodeling in angiotensin II overproducing transgenic mice. Atherosclerosis 2009, 206:54-60.
82. Sontia B., Montezano A.C.I., Touyz R.M. Downregulation of renal TRPM7 and increased cardiovascular and renal inflammation and fibrosis in aldosterone-infused mice-effects of magnesium supplementation. Hypertension 2008, 51:915-921.
83. Callera G.E., Yogi A., Briones A.M., et al. Vascular proinflammatory responses by aldosterone are mediated via c-Src trafficking to cholesterol-rich microdomains: role of PDGFR. Cardiovasc Res 2011, 91:720-731.
84. Savoia C., Touyz R.M., Schiffrin E.L. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008, 51:432-439.
85. Briones A.M., Nguyen Dinh Cat A., Callera G.E., et al. Adipocytes produce aldosterone through calcineurin-dependent signalling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012, 59:1069-1078.
86. Weidmann P., Beretta-Piccoli C., Ziegler W.H., et al. Age versus urinary sodium for judging renin, aldosterone, and catecholamine levels: studies in normal subjects and patients with essential hypertension. Kidney Int 1978, 14:619-628.
87. Hegstad R., Brown R.D., Jiang N., et al. Aging and aldosterone. Am J Med 1983, 74:442-448.
88. Horstmeyer A., Licht C., Scherr G., Eckes B., Krieg T. Signalling and regulation of collagen I synthesis by ET-1 and TGF-β1. FEBS J 2005, 272:6297-6309.
89. Hafizi S., Wharton J., Chester A.H., Yacoub M.H. Profibrotic effects of endothelin-1 via the ETA receptor in cultured human cardiac fibroblasts. Cell Physiol Biochem 2004, 14:285-292.
90. Park J.B., Schiffrin E.L. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 2001, 37:1444-1449.
91. Ammarguellat F.Z., Gannon P.O., Amiri F., Schiffrin E.L. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension 2002, 39:679-684.
92. Ebihara I., Nakamura T., Tomino Y., Koide H. Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis. Nephrol Dial Transplant 1997, 12:1001-1006.
93. Boffa J.J., Tharaux P.L., Dussaule J.C., Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 2001, 37:490-496.
94. Komatsumoto S., Nara M. Changes in the level of endothelin-1 with aging. Nihon Ronen Igakkai Zasshi 1995, 32:664-669.
95. Donato A.J., Gano L.B., Eskurza I., et al. Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol 2009, 297:H425-H432.
96. Tokunaga O., Fan J., Watanabe T., et al. Endothelin. Immunohistologic localization in aorta and biosynthesis by cultured human aortic endothelial cells. Lab Invest 1992, 67:210-217.